Apex Biotechnology Corp. (1733.TW)
TWD 30.7
(6.23%)
TWD 30.7
(6.23%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -201.21 Million TWD | -129.18% |
| 2022 | -87.79 Million TWD | 58.6% |
| 2021 | -212.05 Million TWD | 1.43% |
| 2020 | -215.14 Million TWD | -1687.42% |
| 2019 | 13.55 Million TWD | -91.58% |
| 2018 | 160.91 Million TWD | 442.34% |
| 2017 | 29.67 Million TWD | 118.08% |
| 2016 | -164.13 Million TWD | -89.77% |
| 2015 | -86.49 Million TWD | -138.58% |
| 2014 | 224.2 Million TWD | 74.56% |
| 2013 | 128.44 Million TWD | 178.29% |
| 2012 | -164.04 Million TWD | 47.12% |
| 2011 | -310.21 Million TWD | 40.41% |
| 2010 | -520.62 Million TWD | -292.49% |
| 2009 | -132.64 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -237.23 Million TWD | -17.9% |
| 2024 Q2 | -203.92 Million TWD | 14.04% |
| 2023 Q3 | -96.47 Million TWD | 51.81% |
| 2023 Q1 | -68.13 Million TWD | 22.39% |
| 2023 Q4 | -201.21 Million TWD | -108.56% |
| 2023 Q2 | -200.21 Million TWD | -193.83% |
| 2023 FY | -201.21 Million TWD | -129.18% |
| 2022 Q2 | -248.65 Million TWD | -46.77% |
| 2022 FY | -87.79 Million TWD | 58.6% |
| 2022 Q4 | -87.79 Million TWD | -15.07% |
| 2022 Q3 | -76.3 Million TWD | 69.31% |
| 2022 Q1 | -169.42 Million TWD | 20.11% |
| 2021 FY | -212.05 Million TWD | 1.43% |
| 2021 Q2 | -355.52 Million TWD | -25.62% |
| 2021 Q3 | -194.8 Million TWD | 45.21% |
| 2021 Q4 | -212.05 Million TWD | -8.85% |
| 2021 Q1 | -283.02 Million TWD | -31.55% |
| 2020 Q2 | -35.45 Million TWD | -138.95% |
| 2020 Q4 | -215.14 Million TWD | -606.82% |
| 2020 FY | -215.14 Million TWD | -1687.42% |
| 2020 Q1 | 91.04 Million TWD | 571.73% |
| 2020 Q3 | -30.43 Million TWD | 14.16% |
| 2019 Q3 | 166.43 Million TWD | -41.65% |
| 2019 FY | 13.55 Million TWD | -91.58% |
| 2019 Q1 | 95.21 Million TWD | -40.83% |
| 2019 Q2 | 285.21 Million TWD | 199.55% |
| 2019 Q4 | 13.55 Million TWD | -91.86% |
| 2018 Q4 | 160.91 Million TWD | -11.51% |
| 2018 FY | 160.91 Million TWD | 442.34% |
| 2018 Q3 | 181.84 Million TWD | -48.69% |
| 2018 Q2 | 354.41 Million TWD | 1264.54% |
| 2018 Q1 | 25.97 Million TWD | -12.46% |
| 2017 Q2 | 8.13 Million TWD | 113.34% |
| 2017 FY | 29.67 Million TWD | 118.08% |
| 2017 Q4 | 29.67 Million TWD | -62.97% |
| 2017 Q1 | -61 Million TWD | 62.83% |
| 2017 Q3 | 80.13 Million TWD | 884.57% |
| 2016 Q2 | -224.83 Million TWD | -49.25% |
| 2016 Q1 | -150.63 Million TWD | -74.16% |
| 2016 FY | -164.13 Million TWD | -89.77% |
| 2016 Q4 | -164.13 Million TWD | -77.66% |
| 2016 Q3 | -92.39 Million TWD | 58.91% |
| 2015 Q3 | 202.07 Million TWD | 355.35% |
| 2015 Q2 | -79.13 Million TWD | -134.92% |
| 2015 FY | -86.49 Million TWD | -138.58% |
| 2015 Q1 | -33.68 Million TWD | -115.03% |
| 2015 Q4 | -86.49 Million TWD | -142.8% |
| 2014 FY | 224.2 Million TWD | 74.56% |
| 2014 Q4 | 224.2 Million TWD | -50.39% |
| 2014 Q3 | 451.96 Million TWD | 339.06% |
| 2014 Q2 | 102.93 Million TWD | 282.91% |
| 2014 Q1 | 26.88 Million TWD | -79.07% |
| 2013 Q2 | 206.07 Million TWD | 285.47% |
| 2013 Q1 | -111.1 Million TWD | 32.27% |
| 2013 FY | 128.44 Million TWD | 178.29% |
| 2013 Q4 | 128.44 Million TWD | -37.86% |
| 2013 Q3 | 206.69 Million TWD | 0.3% |
| 2012 Q2 | -72.44 Million TWD | 84.65% |
| 2012 FY | -164.04 Million TWD | 47.12% |
| 2012 Q4 | -164.04 Million TWD | 39.51% |
| 2012 Q3 | -271.2 Million TWD | -274.37% |
| 2012 Q1 | -471.89 Million TWD | -52.12% |
| 2011 Q2 | -598.55 Million TWD | -9.59% |
| 2011 Q3 | -144.77 Million TWD | 75.81% |
| 2011 FY | -310.21 Million TWD | 40.41% |
| 2011 Q4 | -310.21 Million TWD | -114.28% |
| 2011 Q1 | -546.18 Million TWD | -4.91% |
| 2010 Q4 | -520.62 Million TWD | 0.0% |
| 2010 FY | -520.62 Million TWD | -292.49% |
| 2009 FY | -132.64 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Sinphar Pharmaceutical Co.,Ltd. | 870.53 Million TWD | 123.114% |
| Panion & Bf Biotech Inc. | 193.2 Million TWD | 204.144% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 939.54 Million TWD | 121.416% |
| GenMont Biotech Incorporation | 2.71 Million TWD | 7519.432% |
| Abnova (Taiwan) Corporation | -415.8 Million TWD | 51.609% |
| Adimmune Corporation | 685.12 Million TWD | 129.369% |
| Tanvex BioPharma, Inc. | 1.35 Billion TWD | 114.893% |
| Polaris Group | -2.41 Billion TWD | 91.682% |
| Energenesis Biomedical CO.,LTD. | -246.6 Million TWD | 18.407% |
| UnicoCell Biomed Co., Ltd. | 54.43 Million TWD | 469.677% |
| PELL Bio-Med Technology Co. Ltd. | 4.88 Million TWD | 4222.413% |